What You Should Know:
– Miist Therapeutics, a pioneering company developing inhaled medicines with a focus on rapid drug delivery raises $7M ina seed funding round led by Refactor Capital with participation from 1517 Fund, Freeflow Ventures, and others,
– The investment will accelerate the development of Miist’s innovative therapies for smoking addiction and migraine.
Fast-Acting Therapies for Smoking Addiction and Migraine
Miist’s therapies address a significant unmet need for faster-acting and more effective treatments for common and debilitating conditions. The company’s initial focus is on smoking addiction and migraine, which affect millions of people worldwide. Miist’s unique approach leverages physics and engineering to deliver drugs directly to the peripheral lung, where they are rapidly absorbed into the bloodstream. This results in significantly faster onset of action compared to traditional oral medications.
Miist’s proprietary inhaler utilizes ultrasonic vibration to generate sterile, aqueous drug particles small enough to reach the peripheral lung. This approach eliminates the need for heat, ensuring drug stability and patient safety.
Key features of Miist’s inhaled medicines include:
– Rapid absorption: Drugs reach the bloodstream in less than 30 seconds, up to 100 times faster than pills.
– Enhanced efficacy: Direct delivery to the peripheral lung improves drug absorption and effectiveness.
– Reduced side effects: Targeted delivery minimizes systemic exposure and reduces the risk of side effects.
– Improved patient experience: Faster onset of action and improved efficacy enhance the patient experience.
